ENGAGING FORCES AND KNOWLEDGE FOR THE ADVANCEMENT OF SCIENTIFIC RESEARCH
We invest a lot of resources for patients empowerment, stimulating them to be protagonists of the working groups related to the development of new medicines and therapies. Besides research, we perform educational and training activities in the regulatory field with the aim to foster a continuous multi-specialistic update on the complex procedures of the European Pharmaceutical System. Also, we strictly cooperate with national and European institutions in order to make our professionalism and expertise available for the implementation of reasoned and effective policies. Our representatives are actively involved in the activities of the EMA committees, Enpr-EMA (European Network of Paediatric Research), ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance), Italian Ministry of Health, Italian Ministry of Education, University and Research, AReSS Puglia. We are convinced that professional cooperation and the exchange of experiences and expertises is crucial for the scientific progress. This is why we are also involved in the construction and active part of research networks.
PROVIDE METHODOLOGICAL, ETHICAL AND REGULATORY SUPPORT TO THE RESEARCH
The application of methodological expertise can lead to changes in clinical practice, indirectly contributing to a decrease in the costs of medicines and therapies and, finally, promote the allocation of resources on interventions aimed at developing safe and efficient health organizations and structures.
GUARANTEE A PHARMACEUTICAL QUALITY SYSTEM THOUGHT FOR EVERYONE
The pharmaceutical system regulates access to medicines to ensure that when a new drug enters into the market, there is a great evidence on efficacy and safety, so that doctors and patients can make targeted choices. In the European Union the approval of new drugs is centralized in the hands of the EMA.
COLLECT AND ANALYZE DATA TO CREATE A SHARED INTEGRATED SYSTEM
Information technology is a tool for the progress of scientific research, especially in the biomedical field. Distributes and makes available new knowledge in a short time, making the research activity very competitive in economic terms.
WORK ON MEDICINES THAT CAN CHANGE LIFE
Pharmaceutical innovation changes life. Patients should not be left out of progress and care information. A description of European policies in the field of rare diseases and orphan medicines is available on the European Commission website.
PROMOTE THE CENTRALITY OF PATIENT
When a person gets sick and and it turns out affected by a rare pathology, his life changes radically. They are diseases often united by difficulties in diagnosis and lack of information and awareness by institutions and the social-health staff.